Suppr超能文献

[顺铂和5-氟尿嘧啶同步放化疗治疗晚期头颈部肿瘤]

[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].

作者信息

Fietkau R, Iro H, Grabenbauer G G, Altendorf-Hofmann A, Sauer R

机构信息

Strahlentherapeutische Klinik, Universität Erlangen-Nürnberg.

出版信息

Strahlenther Onkol. 1991 Dec;167(12):693-700.

PMID:1763405
Abstract

Between 1.1. 1987 and 31.12. 1988 47 patients with locally advanced head- and neck tumours (UICC-stage II: one patient, stage III: 16 patients, stage IV: 30 patients) were treated with simultaneous radio-chemotherapy. Localisations were hypopharynx (23 = 49%), oropharynx (16 = 34%) and other sites (8 = 17%). Radiation therapy consisted of 60 Gy (primary region, N+) or 50 Gy (N0) in daily fractions of 2 Gy each over six weeks. During week 1 and 5 of radiotherapy two courses of chemotherapy with 5-FU (600 mg/m2/day, i.v. continuous infusion for five days) and cis-platin (25 mg/m2/day i.v. bolus for five days) were administered. 43/47 patients (91%) responded to therapy. 34/47 (72%) patients achieved a complete remission, 9/47 (19%) a partial remission, and 4/47 (9%) no change. With a minimum follow-up of 26 months 17/47 patients (36%) are alive and NED, 4/47 (9%) are alive with tumour. 18 patients (38%) died of cancer, eight patients (17%) died of second tumours, intercurrent diseases and of unknown reasons. Actuarial four-year survival is 45% (stage III: 56%, stage IV: 42%), four-year NED survival is 35% (stage III: 68%, stage IV: 18%). There were no loco-regional recurrences after additional surgical treatment of the primary and the neck following complete remission. In contrast after RCT alone and complete remission local recurrences in 6/21 patients (29%) and regional recurrences in 5/24 patients (21%) occurred. We conclude that simultaneous RCT is a new very effective treatment modality of locally advanced head and neck tumours producing superior loco-regional control compared to conventional management.

摘要

1987年1月1日至1988年12月31日期间,47例局部晚期头颈部肿瘤患者(国际抗癌联盟分期:II期1例,III期16例,IV期30例)接受了同步放化疗。肿瘤部位为下咽(23例 = 49%)、口咽(16例 = 34%)和其他部位(8例 = 17%)。放射治疗包括在六周内每天分次给予60 Gy(原发区域、N+)或50 Gy(N0),每次2 Gy。在放疗的第1周和第5周,给予两个疗程的化疗,使用5-氟尿嘧啶(600 mg/m²/天,静脉持续输注5天)和顺铂(25 mg/m²/天,静脉推注5天)。47例患者中有43例(91%)对治疗有反应。47例患者中有34例(72%)达到完全缓解,9例(19%)部分缓解,4例(9%)无变化。在至少随访26个月后,47例患者中有17例(36%)存活且无疾病证据,4例(9%)带瘤存活。18例患者(38%)死于癌症,8例患者(17%)死于第二肿瘤、并发疾病或死因不明。四年精算生存率为45%(III期:56%,IV期:42%),四年无疾病证据生存率为35%(III期:68%,IV期:18%)。在完全缓解后对原发灶和颈部进行额外手术治疗后,未出现局部区域复发。相比之下,单纯接受放化疗并完全缓解后,21例患者中有6例(29%)出现局部复发,24例患者中有5例(21%)出现区域复发。我们得出结论,同步放化疗是局部晚期头颈部肿瘤一种新的非常有效的治疗方式,与传统治疗相比,能产生更好的局部区域控制效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验